"Biomarking" the transition from genetic risk to kidney disease

Etty Kruzel-Davila; Karl Skorecki

doi:10.1016/j.kint.2018.03.005

"Biomarking" the transition from genetic risk to kidney disease

Kidney Int. 2018 Jun;93(6):1270-1272. doi: 10.1016/j.kint.2018.03.005.

Authors

Etty Kruzel-Davila¹, Karl Skorecki²

Affiliations

¹ Department of Nephrology, Rambam Health Care Campus, Haifa, Israel.
² Department of Nephrology, Rambam Health Care Campus, Haifa, Israel; Department of Genetics and Developmental Biology, Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: skorecki@technion.ac.il.

PMID: 29792270
DOI: 10.1016/j.kint.2018.03.005

Abstract

Only some individuals carrying the high-risk APOL1 genotype go on to develop kidney disease phenotypes. In this issue of Kidney International, Nadkarni and colleagues report the associations of several biomarkers with renal outcomes in individuals with high-risk APOL1 genotypes. In the era of precision medicine, these findings should translate into improved longitudinal risk assessment for this high-risk population and might also provide additional insights regarding sites and mechanisms of APOL1 nephropathy.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Apolipoprotein L1
Apolipoproteins / genetics*
Black or African American
Genetic Predisposition to Disease
Genotype
Humans
Lipoproteins, HDL / genetics*
Risk Factors

Substances

APOL1 protein, human
Apolipoprotein L1
Apolipoproteins
Lipoproteins, HDL